Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bridgepoint Group PLC Board/Management Information 2024

Jul 1, 2024

5352_mang_2024-07-01_fe711627-d5a4-409a-a2f2-9154a2a6c75d.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 6375U

Bridgepoint Group plc

01 July 2024

Bridgepoint Group plc

(" Bridgepoint " or the " Company ")

Director Declaration

In accordance with Listing Rule 9.6.14R, the Company advises that Cyrus Taraporevala, an Independent Non-Executive Director, has been appointed as a Non-Executive Director of Pfizer Inc.

ENQUIRIES:

Bridgepoint

Analysts and investors

Adam Key

[email protected]

+44 7833 748010
Media

Christian Jones / James Murray

[email protected] [email protected]

+44 20 7034 3500

FGS Global (Public Relations Adviser to Bridgepoint)

Charles O'Brien / +44 20 7251 3801 / +44 7825 043 656

Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534 233

[email protected] 

Legal Entity Identifier (LEI): 213800KFNMVI8PDZX472

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNZZGGNZMRGDZM